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ABSTRACT 
A facultative post market monitoring of potential health impacts of genetically modified (GM) 
feedstuffs on livestock consuming these feeds after pre-market risk assessment is under ongoing 
consideration. Within the IPAFEED database, scientific studies on health effects beyond performance 
in livestock and the results of a systematic search for evidence of outcome effects due to GM feed 
are consolidated. These outcomes were reviewed and checked for consistency in order to identify 
plausible syndromes suitable for conducting surveillance. The 24 selected studies showed no 
consistent changes in any health parameter. There were no repeated studies in any species by GM 
crop type and animal species. As such, there is insufficient evidence to inform the design of 
surveillance systems for detecting known adverse effects. Animal health surveillance systems have 
been proposed for the post market monitoring of potential adverse effects in animals. Such systems 
were evaluated for their applicability to the detection of hypothetical adverse effects and their 
strengths and weaknesses to detect syndromes of concern are presented. For known adverse 
effects, applied controlled post-market studies may yield conclusive and high-quality evidence.  For 
detecting unknown adverse effects, the use of existing surveillance systems may still be of interest. A 
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simulation tool developed within the project can be adapted and applied to existing surveillance 
systems to explore their applicability to the detection of potential adverse effects of GM feed. 
 
 
KEYWORDS:  
Genetically modified crops, Animal feed, Animal Health, Surveillance, Post Market Monitoring 
(PMM). 
 
HIGHLIGHTS:  
• No evidence for health impacts of GM feeds on livestock exists to allow the development of 
a surveillance system targeted specifically at such known adverse effects.  
• For detected previously unknown adverse effects tests to determine any potential 
association with GM feed are limited, as such, the use of animal health surveillance for 
detection of adverse effects has significant weaknesses. 
• Type I and type II errors, i.e. the possibility of failing to detect an adverse effect which was 
present and the possibility to detect adverse effects which are not truly present, would 
compromise the utility of any post-market monitoring system for GM feed.  
• The current terminology used in GM feed post market monitoring is not consistent with 
terminology generally used in animal health surveillance.    
• The cost-effectiveness of any surveillance approach for GM feed adverse effect is likely to be 
poor, due to a high cost per animal detected and there is therefore further work in this area 
required.   
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ABBREVIATIONS: 
BIP, border inspection post; EU, European Union; GM, genetically modified; GMO, genetically 
modified organism; OIE, World Organisation for Animal Health; TRACES, Trade Control and Expert 
System 
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1. Introduction 
This paper summarizes the context in which the MARLON project consortium has developed 
an approach to inform monitoring livestock for potential adverse health impacts resulting 
from the consumption of animal feeds derived from genetically modified (GM) crops. The 
acronym MARLON stands for “Monitoring of Animals for Feed-related Risks in the Long 
Term”. The three-year MARLON project was funded by the European Commission under its 
Seventh Framework Program for research and technology development.  
 
One of the main goals of the project was to provide data and approaches that could assist 
with the design of a post-market monitoring program for detection of possible adverse 
health effects in livestock of specific GM crops being sold within the European Union (EU), in 
case there was a requirement to do so. At the time of project initiation (2012), such a 
requirement did not yet exist for any of the GM animal feeds that had already gone through 
the mandatory regulatory approval procedure. This procedure is mandatory for all GM 
foods and feeds before permission can be granted for their market entry within the EU. Part 
of the procedure is a pre-market safety assessment, which may identify also outstanding 
issues that warrant post-market monitoring. This could then become a requirement as part 
of the EU authorities’ decision to allow the GM crop and its derived animal feed onto the 
market. The development of these tools was therefore of a prospective nature.  
 
Towards this end, MARLON brought together the different disciplines of regulatory safety 
assessment of genetically modified organisms (GMOs) and veterinary epidemiology. Whilst 
the first was borne out of a precautionary approach as there were no hazards known to be 
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inherently linked to genetic modification, the latter usually focuses on known hazards such 
as microbial pathogens or on production outcomes. Moreover, the safety assessment of 
GMOs usually entails experimental studies performed under controlled conditions, whilst 
the epidemiological approaches to post-market monitoring would utilise data generated by 
animal health surveillance systems. In order to explore what options are feasible, the 
project considered the background knowledge on potential health impacts of GM-crop-
derived feeds, the possibility to measure exposure of livestock to such feeds, the structure 
of the various feed and livestock production chains and the existing health surveillance 
schemes.  
 
Here, after a summary of the recent history of the introduction of GM crops into the EU 
market, an overview of the various kinds of animal health surveillance systems is being 
provided. It is considered how the latter can be designed and adapted for the purpose of 
monitoring GM feeds for their potential adverse health impacts. Moreover, we explored the 
published literature and data from published livestock feeding studies in the IPAFEED 
database established within MARLON. The purpose was to verify if there are any animal 
health and production parameters that could be used in surveillance for potential adverse 
health effects specifically linked to GM feed intake. While the project specifically focused on 
GM feeds and production chains and regulatory context within the EU, the applicability of 
the project outcomes can easily be extended to other feeds and beyond the EU. 
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2. Background 
2.1. GM-crop-derived feeds 
Over the past two decades, following the commencement of the large-scale cultivation of 
genetically modified (GM) crops obtained through modern biotechnology techniques in the 
mid 1990s, the adoption of these crops has expanded continuously, reaching a global 
acreage of 181.5 million hectares worldwide growing these crops in 2016. Most of these are 
commodity crops such as soybean, maize, cotton, oilseed rape, and rice, whilst the most 
popular traits introduced through genetic modification include herbicide resistance and pest 
insect resistance. While there are 18 countries growing more than 50,000 hectares of such 
crops (1), it is conceivable that, through international trade in raw agricultural commodities 
or derived products, other countries not growing GM crops or only to limited extent may 
still import sizable amounts of these commodities. These could be used, for example, as 
ingredients for the production of animal feeds, such as from maize gluten or oilseed 
(soybean, canola, cottonseed) meals. 
 
2.2. Regulatory pre-market safety assessment & post-market monitoring of 
animal feeds from GM crops 
Before GM crops and food and animal feed products derived from these crops can be sold, 
many countries require that they undergo a regulatory procedure which also entails a pre-
market safety assessment. For such assessments, the internationally harmonized approach 
of comparative assessment is applied, which has been enshrined in guidelines for such 
safety assessments published by the authoritative Codex Alimentarius, of which most 
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nations of the world are members (2), and further elaborated by others, such as the EFSA 
GMO Panel. According to this approach, an extensive comparison of a GM crop with a 
genetically close non-GM comparator with a history of safe use will help identify intended 
and unintended changes brought about by the genetic modification. As such, an extensive 
analysis of molecular, compositional and phenotypic/agronomic characteristics is commonly 
undertaken, after which any differences found are evaluated for their relevance and it is 
subsequently decided whether the information base including any parameter changes are 
sufficient to conclude that the risk of potential safety implications requires additional 
information in the form of monitoring or additional tests (for example, animal toxicity tests). 
 
Whilst in many cases pre-market assessments are sufficiently conclusive, it can be envisaged 
that in some specific cases, it may be desirable to collect further data in the post-market 
stage. This could serve the purpose of verifying whether any assumptions made during the 
pre-market assessment, such as for consumption of the product, need to be adjusted or 
checked for hazards identified during the pre-market assessment. Under EU legislation(3) 
for example, decisions for the regulatory approval of a specific GM product may include a 
clause requiring such case-specific post-market monitoring for a particular feature, such as 
consumption estimates or a hypothetical adverse effect. So far, such requirements have 
particularly been imposed for GM oilseed crops with modified fatty acid composition, for 
which applicants seeking to market them were obliged by the decisions approving their 
commercialization to verify the consumption in subpopulations given the possible impact on 
human nutrition. Such requirements have not been imposed yet by the EU for animal feed 
specifically. Besides the optional case-specific monitoring for possible impacts of specific 
GM crops, applicants in the EU have to perform general surveillance for possible unforeseen 
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health and environmental effects of such crops and their derived products for all GM crops. 
The European biotechnology industry association EuropaBio, for example, has elaborated a 
procedure towards this end. It involves the associations of operators dealing with imported 
viable commodities, which are to be informed of approvals of GM crops that are subject to 
the requirement of surveillance, and reminded to report any unexpected adverse effects 
resulting from the consumption of these ingredients (4).   
 
Also outside the EU, regulatory authorities in charge of safety assessment of GM foods and 
feeds consider the possible need for post-market monitoring under specific circumstances. 
Food Standards Australia New Zealand, for example, notes that the pre-market safety 
assessment already provides assurance and considers general passive surveillance 
impractical, particularly in the absence of a specific hypothesis. It also refers to specific 
scenarios under which case-specific monitoring could be helpful, such as for nutritionally 
altered GM crops, to verify assumptions made during the risk assessment regarding 
nutritional and health impacts of their consumption on the population (5). In the United 
States, the Centre for Food Safety and Applied Nutrition’s Adverse Event Reporting System 
coordinates their passive surveillance system. This system allows consumers to report 
suspected adverse reactions; almost 100,000 self-reported records of events related to food 
consumption were reported within the period January 2004 – June 2017. Few of these 
reports refer to GM foods. Although it is not clear from these records if and what follow-up 
was conducted in response to these reports, it shows that GM foods and feeds are also 
considered to fall within the scope of these reporting systems (6). 
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2.3. The MARLON project 
For the purpose of developing a harmonized approach which applicants could employ to 
establish case-specific monitoring initiatives, if required by EU decision makers, to check for 
specific health impacts of a particular GM feeds, the EU-funded MARLON research project 
was initiated in 2012 (7). Within this three-year project, various factors that could enable 
the establishment of a post-market monitoring initiative were explored, such as background 
knowledge on possible health impacts of GM feeds in livestock, insight into the organization 
and information flow within animal production chains and the possibility to measure 
exposure of livestock to GM feed ingredients as well as indicators for four pre-identified 
health impacts. Importantly, the project also sought to develop a simulation tool that could 
assist applicants in assessing whether a certain hypothetical adverse effect on animal health 
could trigger a trend deviating from the background pattern of ‘normal’ health and 
production parameters taking into account a range of factors and actors, such as the 
responsiveness and actions of farmers, veterinarians, reporting systems, diagnostic 
laboratories, as well as the specifics of the organization of the livestock production and 
health monitoring systems. Such a probabilistic tool would help to assess the ability of a 
system based on existing animal health and production data to detect a hypothetical effect 
in the livestock population of interest. 
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3. Animal health surveillance and its applicability to GM feed post-
market monitoring. 
The approach to be developed within MARLON had to focus on assessing the usefulness of existing 
surveillance systems for animal health. Such systems, in a more general sense, are an ongoing 
requirement for animal trade and production management (8), whilst none has been specifically 
developed to assess potential adverse health impacts of GM feeds. The data generated through 
national surveillance systems are able to support policy decision development regarding animal 
health management. National systems also provide evidence of disease freedom and early detection 
of outbreaks for national and international organizations (9). The process of surveillance consists of 
data collection, analysis and interpretation; and the outputs are used to inform decisions on animal 
and public health prevention interventions (e.g., (10, 11). The potential use of existing animal health 
surveillance systems for monitoring of GM feed adverse effects has been discussed (12, 13). These 
authors recommend involving farmer and producer organizations into sentinel surveillance networks 
and have also developed sample questionnaires for reporting of a broad range of generic health 
conditions. They also acknowledge that monitoring indicators will depend on the pre-market risk 
assessment pathways and knowledge gaps (12). We have reviewed current practices of post-market 
monitoring of biotechnologically enhanced feed stuffs, attempted to find any evidence for indicators 
which may have higher risk.  With a view to adapting existing animals health surveillance systems to 
include GM feed adverse effect detection.  
 
3.1. Overview of types of surveillance used in animal health 
Many animal health surveillance systems are in place, the functions of these include, providing 
evidence of disease freedom, early detection of disease outbreaks, and estimation of the 
prevalence/incidence of endemic diseases. Broadly, surveillance can be categorised based on the 
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objective of the system. The accuracy of the surveillance system will vary depending on the number 
of animals (or farms) observed, the diagnostic test used and the statistical confidence level required. 
For example, an animal health system which aims purely to determine the prevalence of  an 
endemic disease will be set up entirely differently from a surveillance system aimed at establishing 
freedom from disease or early warning of an emerging concern (10). Below, we review the different 
types of surveillance systems that might be of relevance for the purpose of providing input to post-
market livestock health monitoring initiatives. 
 
3.1.1. Syndromic systems 
A syndrome is a group of symptoms and signs that collectively characterize a particular disease. 
Syndromes are therefore usually non-specific, in contrast to a laboratory confirmed diagnosis. 
Syndromic surveillance can have a variety of purposes, such as detection of emerging, possibly 
unknown threats to animal health, early warning at the start of an unexpected event, situational 
awareness of threats on a day-to-day basis, and reassurance of a lack of impact of known health 
threats (14).  
 
Syndromic surveillance systems are based on regular timely reporting of symptoms associated with a 
specific syndrome. These reporting activities can be either by lay reporting or veterinary reporting 
and are usually passive in nature (15). Syndromic surveillance relies on detailed historical data 
analysed to ascertain the expected level of occurrence. An alarm is triggered when reporting 
exceeds expected levels, this in turn allows for animal health professionals to investigate the cause 
of this alarm (15). 
 
A recent review by Rodriguez-Prieto and co-workers systematically investigated the scientific 
literature on animal health syndromic surveillance systems (16). This followed a previous review in 
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2011, which had concluded that, at that point in time, the field of syndromic surveillance was 
starting to grow fast. In particular, the review considered the different data sources used as inputs, 
animal populations being surveyed, and the particular system’s stage of development. It also 
considered published studies on statistical methods and detection of disease outbreaks that can be 
applied for this purpose. The various data sources identified were categorized as follows: 
• Production data: For example, milk production and reproduction in cattle;  
• Clinical data (primary data): For example, syndromes reported by veterinary practitioners;  
• Clinical data (secondary data): For example, carcass necropsy findings; 
• Laboratory data: For example, laboratory analyses of pathogens in samples collected; 
• Mortality data: For example, weekly reports from national animal registries and renderers; 
• Abattoir data: For example, periodic reports on carcass condemnations and types; 
• Media sources: For example, media reports on livestock disease outbreaks; 
 
Interestingly, the EU-funded Triple-S project published its guidelines for the design and execution of 
syndromic health surveillance plans in 2013, covering both human and animal health (14). It 
considers the following stages in the development of a syndromic surveillance system: 
• Setting up a system, based on a needs assessment (e.g. data gaps, availability of syndrome 
data from existing data sources), definition of purpose and possible synergies with existing 
systems, assignment of roles and tasks to staff and contacts, operational and 
legal/governance provisions, and resource planning. 
• Collecting data, and preparing them for analysis, based on identification of data sources (e.g. 
veterinary clinics, slaughterhouses, laboratories, professional networks, pharmaceutical 
sales, tele-health reporting, passive reporting, renderers, national livestock registries), 
selection of variables to be collected (with a distinction between denominator and 
numerator, such as population size and number of symptom reports within a given time 
interval; including, for example, animal species, demographic, geographical and temporal 
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data preferably also with indications of severity), data coding, data recording, transmission 
and centralization, and data aggregation. Also important are ensuring continuity of data 
access, and safeguarding confidentiality, security, and quality of the data. 
• Analysis of data, distinguishing between prospective analysis, i.e. early event detection and 
reassurance of no health impact, and retrospective analysis, i.e. post-hoc quantification of 
health impacts allowing for the use of more complex calculation methods, also taking into 
account various internal and external factors. The following key steps can be discerned: 1) 
preparation of aggregated data as indicators (absolute or relative) for statistical, 
epidemiological analysis; 2) choice and application of appropriate statistical methods taking 
into account purpose, data characteristics and accuracy; 3) checking of data for 
epidemiological relevance (e.g. contact data source, compare with data from other systems, 
verify if other statistical methods would have yielded different outcomes); 4) risk 
assessment, including a characterization of the threat and public health impacts; 5) 
translation into public health measures. 
• Communication of the outcomes to different groups of stakeholders, such as decision 
makers, surveillance system participants, actors taking part in other surveillance systems, 
and the general public (15). 
 
From these considerations, it becomes evident that the establishment of syndromic surveillance 
systems requires organizational measures beyond the actual collection, processing, and 
interpretation of data. This also by and large holds true, in more general terms, for the other types 
of surveillance discussed in the subsections below. 
3.1.2. Risk-based surveillance 
With this approach, the data collection will be stratified, taking into account existing knowledge 
about variation of disease risk within the population. This will guide the planning, design, and 
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implementation of surveillance plans. The knowledge on risk variation can be based, for example, on 
historic data, risk profiles, or outcomes of modelling exercises. The identification of factors that 
impact risk can be supported by different types of evidence, including epidemiological studies, 
opinions elicited from experts, and risk assessments (17). Factors that may indicate increased or 
decreased risk include, for example, veterinary health checks, trade and long-distance movement of 
livestock animals, farming intensity and other husbandry practices and farm characteristics, 
geographical location, and animal age (infectivity window). An appropriately designed risk-based 
surveillance should achieve at least the same likelihood of early detection of disease while improving 
the cost-effectiveness of the surveillance activities. 
 
Risk-based surveillance may utilise active and/or passive surveillance approaches. A study 
commissioned by the European Food Safety Authority’s (EFSA) GMO Panel has worked on describing 
the probability of detecting a GM crop-related adverse effect on plant and animal health through 
active reporting systems involving networks of farmers and producers throughout the production 
chains. The authors concluded that adequate sensitivity would be difficult to achieve for rare 
adverse events even if there were great awareness, representativeness and coverage of the samples 
taken (12). The benefits of a passive system are that it is cheap and constantly ongoing in the 
background. The pitfalls are that use of the system is non-specific, sampling is delayed until after a 
concern has been raised, and under reporting is common (18). Another potential limitation of using 
a passive surveillance system is that  data are lacking to support the relationship between the health 
outcome and a specific GM product. (19, 20).   
 
Interestingly, the EU-funded RiskSur project developed a guidance for best practice towards risk-
based and cost-effective animal health surveillance systems. This was done in preparation of the 
implementation of the new EU Animal Health Law (21), which attaches great value to information 
gathering such as surveillance to inform eradication, control, contingency planning, and awareness 
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of diseases. The EU Animal Health Law also created more flexibility for EU member states with 
regard to risk management measures, of which surveillance was supposed to constitute an 
important part, particularly in order to allow for risk-based and cost-effective monitoring (17). It can 
be envisaged that risk-based approaches also have value for other global regions outside the EU. 
 
The RiskSur best practice guidance acknowledges that prioritization is a key initial step in the process 
of establishing risk-based surveillance (17). This will consider the wide-ranging impacts of animal 
disease on, for example, animal health, animal welfare, public health, and societal, economic, and 
environmental aspects. Besides the data and experts’ opinions on these impacts, it also needs to 
consider decision makers’ and other stakeholders’ preferences. Planning of surveillance to identify 
prioritized hazards should include evaluation of the applicability of the existing surveillance systems 
to provide such data.. Once it has been decided to establish a surveillance scheme, its design needs 
to comprise one or more surveillance components, each of which focuses on the occurrence of 
clearly defined cases (17).  
 
The design should consider the hazard, population at risk, spatial and temporal context. This design 
may be different depending on the specific  purpose of the system. Data collection may be 
performed in a risk-guided manner through weighting the sample size calculation by the risk to 
reduce overall sample size, and by selectively sampling a given proportion of the total quantity 
through selectively targeting higher-risk strata. If risk-ratios are known, they can be used to infer the 
overall disease prevalence from the risk stratum specific observations (22, 23).  
 
Implementation requires clear assignment of roles and responsibilities, and awareness raising 
amongst stakeholders who can provide inputs to the system. Data management measures and 
information needs to be in place to collect and process data, while reporting practices need to be 
established both internally and externally with, for example, policy makers and the general public. 
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Finally, the surveillance activities should be subject to evaluation, which in turn has to be performed 
in a cost-effective and efficient way. To this end, RiskSur had developed a tool (EVA-TOOL) that 
guides the formulation of questions. Evaluation can take place at different stages of the surveillance 
undertaking and can be triggered by changes in the context, such as local disease outbreaks, 
changed control options, and public health issues. The final surveillance plan should document all 
features wkth sufficient level of detail as recommended by the World Organisation for Animal Health 
(OIE), for example purpose, populations, resources, activities, roles and responsibilities, end-
products, the supporting information system, dissemination & reporting, and evaluation of the 
surveillance system (17).  
 
3.1.3. Surveillance based on data collection point 
Examples of collection points for this type of surveillance include abattoir surveillance, market 
surveillance, and dip tank surveillance. These modalities are commonly used for infectious diseases 
and public health concerns to reduce the spread of zoonotic disease and early detection of emerging 
conditions. These collection points fit into both active and passive surveillance schemes. Abattoir 
inspections, for example, have the advantage that they are relatively affordable, commonly carried 
out in all except for the smallest abattoirs, and performed on large numbers of animals, whilst these 
inspections are done by skilled staff. Drawbacks are that the data may be biased by, for example, 
samples that are non-representative for the whole population and selection of certain carcass parts 
for inspection. Moreover, certain lesions and observations may be caused by multiple conditions. 
Abattoir data could therefore well fit into syndromic surveillance schemes described above (19). 
 
3.1.4. Checkpoint / quarantine / export station surveillance 
The purpose of this type of surveillance is to ensure detection of notifiable diseases prior to export 
or import. The Terrestrial Animal Health Code and Aquatic Animal Health Code of the OIE stipulate 
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that member states should ensure that border posts and quarantine stations (frontier posts for 
aquatic animals) are organized and equipped with a veterinary service. This should endow the posts 
with the ability to inspect incoming live animals and carcasses for diseases, detect and isolate 
diseased animals, and carry out disinfection and disinfestation (24, 25).  
 
The EU, for example, has to approve “veterinary border inspection posts” (BIPs) within the EU and 
associated countries (Iceland, Norway, Switzerland). BIPS are located at points of entry into the EU 
at airports, ports (canal, river, and sea), roads, railways, and inside the country. For the import of live 
animals from outside these European countries, a health certificate, i.e. the Community Veterinary 
Entry Document, has to be issued by the centralized TRACES database (Trade Control and Expert 
System). The documents and the animals themselves will be checked at the BIP by an official 
veterinarian, while additional checks may also be performed by a veterinarian at the final 
destination. Besides live animals (livestock, equids, companion, laboratory animals, etc.) and 
carcasses, border inspections may also cover imported foods and feeds of animal origin, animal-
material-containing waste from international means of transport, and animal feeds. Issues 
considered include animal health, animal welfare, and veterinary public health (26). Results of 
veterinary checks at BIPs will be reported through TRACES, which allows, for example, for monitoring 
of health and quality of consignments under scrutiny (e.g. meat from countries for which mandatory 
checks have been imposed due to health or safety concerns. It can be envisaged that such data on 
checks, including the reasons for rejection or detention, would be amenable to inclusion in 
surveillance schemes, such as for syndromic surveillance discussed above. 
 
A parallel investigation within the MARLON project reviewed the organization of various animal feed 
and livestock production chains in Europe, including also the various types of inspections and 
controls, such as BIPs. The purpose was to explore whether data on the presence of specific GM feed 
ingredients can be traced throughout the production chain and which animal health checks and 
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controls would lend them for use during surveillance. It was concluded, among others, that within 
the EU, legislation has enabled the tracing of livestock for the purpose of animal identification and 
monitoring for infectious diseases (27). 
3.1.5. Sentinel herd / flock - sentinel surveillance 
This type of surveillance relies on identifying specific herds or flocks which may act as pre-warning of 
the disease. For sentinels used for surveillance of infectious animal diseases, important in the choice 
and use of a sentinel is its response to the hazard (pathogen in case of infectious disease):  The 
sentinel should be susceptible to the same disease as the total population of interest. Sentinel 
populations are often, although not exclusively, populations for which the probability of detecting 
the outcome of interest is increased. This may be due to a higher exposure to the hazard or 
pathogen, or more rigorous monitoring (28).   
Translated to the hypothetical scenario of surveillance of livestock for health impacts of GM feeds, 
sentinels could be animals which may be more susceptible or which consume consistently more GM 
feed.  
 
3.1.6. Representative survey 
A representative survey is a probabilistic survey which is often used to establish disease prevalence 
performed as an active surveillance activity. Achieving the desired level of certainty requires a 
sufficiently large sample size, which can be impractically large for low prevalence conditions if a 
small relative error is required. The bias introduced by imperfect tests or means of ascertaining 
disease status should be considered and the apparent prevalence adjusted on the basis of the 
sensitivity and specificity values to obtain the likely true prevalence.  
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3.2. Evaluation of surveillance systems 
The evaluation of surveillance systems helps to establish the level of certainty with which either a 
region can be defined as disease-free or the bounds (range) of prevalence can be estimated. The 
strength of the confidence in this range can also be calculated and expressed based on the size of 
the sample and assuming it is representative of the reference population. For example, an outcome 
could be “95% confidence that the prevalence of the disease syndrome in the target population is 
5% with a precision of +/- 1%.”  Furthermore, with a pre-defined level of precision and confidence 
required, it is possible to calculate the number of farms and animals which would need to be 
monitored while considering variables such as the risk of a disease occurring.  
 
3.2.1. Sensitivity, specificity and misclassification 
The sensitivity of a surveillance system is the ability of that system to correctly detect animals as 
positive given that they have a syndrome. Similarly the specificity of the surveillance system can be 
defined as the ability of the system to correctly detect animals as not having the disease given that 
they are healthy. In the context of post-market monitoring of potential adverse effects of GM feed, 
the sensitivity can be defined as the probability of this system to detect an abnormal health effect 
given that a true abnormal health effect has occurred. Whilst, the specificity of the system can be 
considered as the proportion of instances where the system will detect only truly abnormal health 
effects, and not cases which may be attributable to other conditions. Misclassification can occur 
where a system fails to identify an abnormality as abnormal, or where a normal parameter is 
wrongly classified as abnormal.  This can be due to bias in sampling, measurement error, test 
interpretation etc. This misclassification will impact the system sensitivity and specificity for 
detecting abnormalities.  
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3.2.2. Errors to consider in animal health surveillance 
The risk of type I error is the probability that the surveillance system produces information that leads 
to the making of a decision when the real state of the population would not require it. That is, Type I 
errors imply that decisions are unnecessarily made leading to unnecessary expenditures. For 
example, in the context of monitoring potential adverse effects of GM feed, this would be the 
system detecting adverse effects and attributing them to GM when the perceived adverse health 
effect might be due to random error or is not actually outside of the normal variation. Similarly, the 
risk of type II error is the probability that an abnormality is undetected in the population. In other 
words, this is the probability that the surveillance system produces information that does not lead to 
the making of a decision although the true state of the population would require it. Type II errors 
imply that no decisions are made despite a genuine health issue occurring. With relation to GM 
products, this concern of missing adverse effects and failing to act is often cited by critics, whilst 
consideration to mitigating Type II errors through surveillance evaluation, should post market 
monitoring be enforced, would undoubtedly be of interest.  
 
3.2.3. Consistency and Integration of surveillance systems.  
The use of surveillance data to contribute towards rigorous scientific evidence poses many 
challenges. This is the case in the context of animal health diseases as well as potential adverse 
effects of GM feed. Surveillance systems currently in place are largely specific to a single disease and 
difficult to adapt to general conditions (10). Furthermore reporting is variable between countries 
and when surveillance is implemented for a specific condition, the usefulness of the data when 
applied to a different syndrome or condition needs careful consideration. Performing unnecessary 
surveillance is a concern particularly when resources are limited and is of interest when considering 
post market monitoring when there is little evidence of risk. The cost of implementing surveillance 
may be unjustifiable if the evidence can be obtained more accurately through other scientific 
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investigation methods. Data sharing between countries remains a challenge, and with such a 
widespread usage such as GM feed, the strength of evidence required to establish any minor 
unknown effects attributable to GM feed could be greatly enhanced through multi-country 
reporting.  
 
3.3. GM feed background 
At present, decisions about the long term safety of genetically modified plants are made based on 
the results of risk assessments which consider a weight of evidence consisting of a broad range of 
data, which may or may not include controlled animal studies. The information in surveillance 
systems has the potential to be analysed to contribute to the longer-term monitoring of the effects 
of GM plants fed to animals.  
 
To date, there are some attempted surveillance initiatives which are conducted to satisfy the 
requirements of post-market monitoring as and where it is recommended, such as for monitoring 
for possible environmental impacts of the cultivation of insect-resistant MON810 maize and for 
actual consumption of soybean oil with modified fat composition from imported GM soybeans used 
as food (29). The objective of case-specific monitoring, is to identify the possible health effects which 
have been recognised in the pre-market safety assessment. Contrary to general surveillance of 
GMOs released into the environment, case-specific monitoring is not mandatory at this stage, but 
decided based on the outcomes of the pre-market safety assessment.  
 
If implemented, it is speculated that surveillance for GM feed adverse effects in animals will likely 
follow a similar principle to that adopted for the plant’s environmental impact monitoring (13). This 
involves two distinct types of post-market activities which are similar in rationale to the system 
which is undertaken in the environmental risk assessment of GM crops (under Directive 2001/18/EC 
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(30)), namely:  Case- Specific Monitoring and General Surveillance. The terminology is not consistent 
with that commonly used in Animal Health Surveillance.  
 
3.3.1. General surveillance 
Reports of presumed adverse effects are recorded passively after notification from farmers and 
other stakeholders. Regular data gathering using targeted questionnaires may be conducted 
depending on the animal consumption of types of GM crops. General surveillance is compulsory and 
a plan must be in place for all new GMOs. It is targeted to specifically identify unknown conditions. 
This usually entails the use of farmers’ questionnaires to assess farmer’s perception of symptoms or 
adverse effects which may have been noticed since the introduction of a new GM crop. The difficulty 
with such methods is that a change or symptom noted after the introduction of the novel GMO does 
not in itself imply the effect was due to the latter. Feedback is also solicited from feed processors 
and handlers if they have become aware of adverse effects. The case definition for adverse effects is 
non-specific, which increases the likelihood of reporting, however it reduces the probability that the 
effects seen may be attributable to the GM product (i.e. reduces the specificity of the system). An 
example of this system working successfully includes the farmer reporting an increase in production 
following the introduction of insect-resistant maize. Presumably, this is related to the decreased 
mycotoxin contamination of this maize. This monitoring is performed to satisfy the requirements 
posted by Directive 2001/18/EC on the deliberate release of GMOs into the environment (30). 
 
3.3.2. Case-specific monitoring 
Whilst no practical example exists as yet of case-specific monitoring of GM-feed impacts on livestock 
health as this has so far not been requested, this type of monitoring has been recommended for 
selected GM strains such as vegetable oils from GM soybean primarily used as ingredients for human 
food. The rationale for this stems from the need for verification of limited pre-market risk 
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assessments with regard to feed intake measurements. This type of monitoring has hereto not been 
recommended for the surveillance of animal feed. Other activities at a national level include regular 
sampling of food products, the objective of which is to ascertain if labelling is reliable. It may be 
possible to combine case-specific monitoring with future DNA analysis in the unlikely event of a large 
unknown adverse effect occurring.  
 
Typically, animal health surveillance systems follow a specific approach identifying the target 
population and the disease of interest with a precise case definition. Tests with known sensitivities 
and specificities to confirm a ‘true’ case are standard. These are not available for any known GM 
feed adverse effect. As such the level of detailed planning yielding high confidence in the results for 
surveillance of GM feed adverse effects is not possible. When planning animal health surveillance 
activities, the first role is to specify the outcome and purpose for such surveillance activities. The 
definitions currently used by either general surveillance or case specific monitoring are broader than 
that used in conventional health surveillance. As such, specific recommendations at this time maybe 
premature; however, consideration to the options available is outlined in this paper. 
 
3.4.  Applicability of health surveillance to specific scenarios 
Within a parallel activity of the MARLON project, the possibility to measure health indicators linked 
to various hypothetical scenarios was explored, such as potential allergenicity of GM feeds in 
livestock, horizontal gene transfer, and positive nutritional impacts of nutritionally improved feeds 
or reduced toxicity given reduced levels of natural toxins contaminating the crop (31). Also, the 
scenario of unknown adverse effects was considered. For this review, we considered how the 
various types of surveillance system could contribute to the detection of such impacts, if they were 
to occur, and what their strengths and weaknesses were as summarized in Table 1. What can be 
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inferred from this table is that all systems do have their strengths and weaknesses, which need to be 
considered when designing a post-market monitoring system.  
 
<<<<< INSERT TABLE 1 AROUND HERE >>>> 
 
4. Review of health parameters potentially amenable to monitoring 
4.1. Database search 
4.1.1. Database 
A database was constructed to compile scientific research which compares livestock' productivity 
and health parameters of animals fed with GM feeds with animals fed with non-GM feed in a 
controlled manner. The studies selected for inclusion into the database had to cover health 
parameters (for example, clinical pathology such as serum biochemistry and haematology) beyond 
merely productivity and performance of livestock animals being fed GM crop-derived feeds, which 
has been the topic of numerous publications. As the outcomes of the literature investigations of De 
Vos and Swanenburg (32) showed, the number of papers providing such additional health 
parameters for production animals is more limited, i.e. 27 articles in the period 2006-2016. The aim 
of this exercise was to provide a repository of evidence and compile all scientific research pertaining 
to potential health effects beyond performance (e.g. haematology) in production animals related to 
consumption of GM varieties of cotton, potato, rice, soya and maize. The IPA Feed database 
provides the repository of published literature relating to genetically modified feed effects in 
production animals (33).   
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The search of original research articles was performed using Scopus (34), a large abstract and 
citation database of peer-reviewed literature using the following search string: TITLE-ABS-KEY ( 
"genetically modified"  OR  "genetically engineered"  OR  biotech*  OR  transgenic )  AND  TITLE-ABS-
KEY ( cattle  OR  dairy  OR  cow*  OR  goat  OR  rabbit  OR  farm*  OR  fish  OR  poultry  OR  chicken  
OR  hen  OR  pig*  OR  sheep  OR  calf )  AND  TITLE-ABS-KEY ( fed  OR  feeding  OR  consumption  OR  
diet )  AND  TITLE-ABS-KEY ( maize  OR  corn  OR  rice  OR  soybean  OR  soya  OR  rapeseed  OR  
potato ).  
 
In order to be included in the database, a study needed to fulfil each of the following criteria: 
• Relevant populations: Cattle (bovine), pig, sheep, goat, poultry and fish; 
• Relevant exposure: Feed containing, consisting or produced from GMOs; 
• Relevant comparator: Feed containing the non-genetically modified conventional 
counterpart of the respective GMOs; 
• Relevant outcomes: Measurements of any growth, health and productivity parameters. 
 
One reviewer performed the selection of the studies which fulfilled the inclusion criteria at three 
stages. At first, articles were selected based on their title to remove clearly irrelevant studies from 
the overall search results, this was followed by a second stage in which the inclusion criteria were 
applied to the abstracts of the articles. In the third stage, the full-text articles were reviewed for the 
presence of each of the elements needed for their inclusion. 
 
Details about the performed experiments were extracted from the "Materials and Methods" section 
of the papers, while the measurements of growth, health and productivity parameters were 
extracted from the tables and graphs as provided by the authors into a standardized data extraction 
sheet.  
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4.1.2. Database search and inclusion criteria 
A database search was performed systematically by species followed by each transformation event 
of GM feed. Studies were identified for inclusion if they showed a statistically significant change in 
one or more health or product quality-related parameters. A critical assessment of this literature 
was subsequently performed identifying all studies with robust methods and statistically significant 
results and extracting these to compile candidate parameters for evaluation. Evaluation of 
coherence between authors was conducted to establish if outcomes could be included in a meta-
analysis. All outcomes for which there was a statistically significant effect were analysed for their 
suitability as outcomes for monitoring in surveillance systems. Hypothesised adverse syndromes 
were subsequently used to consider the strengths and weaknesses for their potential for detection 
in various different surveillance systems.  
 
Whilst statistically significant effects were at the focus of this investigation, it has to be emphasized 
that there is a distinction between statistical significance and biological/toxicological relevance. For 
example, the changes observed may still be due to random error, i.e. the chance that the observed 
outcome is not a true reflection of the study population because statistical significance at P<0.05 can 
be due to random chance in 1/20 cases. The magnitude of any change should also be evaluated. For 
many of the parameters, the cut-off is not a binary variable and as such statistically significant 
results, even of small effect size should be treated conservatively for biological significance. It should 
be noted that even when the differences observed in the study reflect true differences in the study 
population statistical significance does not imply biological relevance or indeed causation and that 
whether an identified association is likely to reflect cause-effect relationship should be carefully 
considered in light of a number of criteria such as the strength of association, the existence of a dose 
response relationship, temporality, biological mechanism, repeatability, etc.. This consideration 
appears particularly relevant since many of these studies evaluate multiple biochemical markers 
increasing the probability of identifying an association as statistically significant by chance (35). 
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Whilst our study focused on the isolated parameters showing statistically significant differences in 
the various studies, there was no contradiction among the authors of the selected publications 
regarding the lack of biological significance of these findings, i.e. there were no parameters which 
fulfilled sufficient criteria to infer that consumption of GM feed was a risk factor for their outcome. 
 
4.2. Identification of candidate health and production parameters.  
Besides the identification of health and production parameters for which statistically significant 
changes were reported, the authors explored whether there was any consistency in such effects 
reported for GM feed consumption and whether the design of the studies would allow for a 
quantitative meta-analysis of the results. Whilst there are numerous studies (n = 24) which identified 
one or more statistically significant change in parameters, there is no GM crop event for which 
multiple studies have been conducted in the same animal species investigating health parameters 
beyond solely performance. As such, it is not feasible at this time to conduct a meta-analysis to 
establish aggregated evidence. 
4.2.1. Poultry 
Significant changes accrue in a study using lysine maize, a GM variety designed to improve nutrition 
as an alternative to direct addition of supplemental lysine to poultry diets. In this study, an increase 
in the rate of weight gain and feed efficiency of the birds fed with lysine maize compared to the 
group fed with non-GM without supplemental lysine was observed (36). Changes in the oxidation 
reduction potential of the breast muscles as well as in the values of thiobarbituric acid reactive 
substances where observed when broilers were fed with insect resistant maize and glyphosate 
tolerant soybean meal (37). Researchers also observed 3.7% decrease of the daily feed intake in 
male broilers fed with herbicide tolerant soybean (38). A tendency for higher egg weights was 
observed in Bt-maize-fed laying hens (39). There was a boost in the immunity against a protozoan 
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disease after feeding chickens with recombinant antigen expressing GM potatoes (40). Over 50% of 
the differences observed in these studies appear to be beneficial; as such, there is insufficient 
evidence to substantiate targeted surveillance in poultry. 
4.2.2. Fish 
In fish, the evidence appears to vary within the different studies. For herbicide tolerant soybean, 
there is an observed increase in feed consumption and final weight in catfish (41). A feeding study 
with Atlantic salmon reports minor differences in the thermal growth coefficient for the group on a 
diet containing insect resistant GM maize, in the plasma triacylglycerol values for herbicide tolerant 
GM soy diet and in hepatosomatic index for the both diets (42). Slightly lower feed intake, growth 
rate and final body weights were observed in the same species for the group fed with insect 
resistant GM maize compared with the group fed with its near-isogenic parental line (43). In an 
analogous study, changes in the nutrient metabolism, indicated by reduced whole-body lipid content 
and lipid retention efficiency, were reported (44).  
4.2.3. Porcine 
There is no or little evidence of adverse or beneficial effects in feeding studies involving pigs since 
none of the reviewed publications have reported any significant differences in the health parameters 
after consumption of GM containing feeds. 
4.2.4. Bovine 
In cattle, statistically significant but inconsistent differences (occurring once during two lactation 
periods) have been reported. They include a decrease in body condition score and back fat 
thickness, an increase in milk protein, milk urea concentration (45), and, in a different study and in 
contradiction to the previous one, an increase in body condition score (46). A decrease in serum 
blood urea nitrogen and glutamic-pyruvic acid transaminase has also been observed in a different 
study (47). These findings do not appear to be repeatable whilst the maize varieties fed in each one 
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contained different genes and originated from different transformation events (MON810, DAS-
59122-7 & CBH 351).  
4.2.5. Multiple species 
There has also been a comparison of health and performance in pigs, cows, goats and poultry before 
and after the large-scale introduction of GM crops into the feed supply chain over a 30 year period 
(48). The authors measured and reported parameters which were similar and hence not indicative of 
an adverse impact due to GM. These differences between studies of adverse effects possess 
significant challenges to identifying syndromes of interest to monitor or areas of risk which would be 
required in constructing surveillance programs. The variety and lack of repeatability in observed 
effects does not provide strong evidence for use of these parameters in animal health surveillance 
systems.  This aligns also with our findings in the subsections above, namely that whereas some 
variables which showed statistically significant differences between animals fed GMO’s and animals 
not fed GMOs. 
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5. Discussion 
Monitoring in the face of uncertainty may allow for early detection of plausible adverse effects; 
which, could then be investigated to ascertain if GM feed were a possible cause. Considering the 
shortage of evidence for adverse animal health and production issues related to GM feed 
ingredients, however, identifying specific variables to record and test in a proposed surveillance 
system is challenging. Possible monitoring could consist of unexpected or expected animal health or 
production syndromes (e.g. through post-mortem inspections, (22, 23, 49)).  
 
Unexpected events would be best evaluated via an active reporting system. Mönkemeyer and 
Schmidt (12) have evaluated using the sentinel surveillance at farm level for detection of health and 
production outcomes, which cannot be foreseen with some success unless it is ensured that 
attributes such as representativeness, coverage, awareness, and sensitivity are addressed. 
 
It may be possible to use existing animal health surveillance and production data to act as an early 
warning system for potential adverse events. Large-scale data collection is undertaken (10), which 
would likely provide indications should change related to GM feed consumption occur. The 
interpretation of this data to   inform decisions relating to GM feed, must consider the original 
purpose for which data were gathered and the target which the  surveillance system the designed to 
evaluate. Possible objectives could be early warning or detection of unknown risks or estimation of 
prevalence, or evaluation of trends of known low-impact risks. However, these two objectives 
require a completely different surveillance design and implementation.  
 
A possible comparison between organic and non-organic farming was considered but this was 
discounted due to concerns that any changes detected would be associated strongly with the 
farming system, not necessarily the exposure of interest (27). A similar reasoning would also apply to 
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a comparison of different member states, for which it is more likely that any differences observed 
between member states would be related to differing farming practices and not attributable to the 
consumption of GM feed. Though unconfirmed and not attributable to GM feed, the changes in 
health parameters observed in the feeding studies within the IPAFEED database are often 
proportionally small in the degree of change. Detection of such identified changes through a means 
such as surveillance would require investment on the scale as to make it unfeasible.  Due to these 
challenges, it could be considered that the strength of evidence which would be provided through 
strengthening the current surveillance systems specifically for animal health adverse effects to GM 
feed would be weak. Robust cost-effectiveness analysis in the face of so much uncertainty is not 
feasible but it is reasonable to suppose that the monetary cost per case detectable would be high. 
 
If post market monitoring of hypothetical effects was deemed necessary then alternative methods 
such as real world experimental controlled longitudinal studies would be more appropriate. 
However, unknown adverse effects could be considered in terms of sentinel surveillance as an early 
warning system. This is perhaps the most useful possible application of surveillance in relation to GM 
feed. 
 
Data generated by surveillance systems are most of the time imperfect. The characterization of the 
epidemiological status of the population produced through the analysis and interpretation of such 
data nonetheless informs decisions. Combination of tests in either series or parallel is frequently 
used to increase either the sensitivity and, or the specificity of the surveillance system.  As such the 
combination of detection methods could be used to improve sensitivity of detection of GM feed 
adverse effects (50).   As the probability of detecting abnormalities through conventional animal 
health surveillance systems is low given the lack of data to support observed health impacts in 
livestock studies performed so far, this combination approach may help to improve sensitivity of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Surveillance Systems for Post Market Monitoring of GM Feed 
 
detection.  For example detection of  a similar syndrome through multiple countries or surveillance 
methodologies may indicate the need for further investigation.    
 
However, for unknown adverse effects, sentinel surveillance could be considered as an early warning 
system. In these cases, further investigation would entail closer scrutiny, which could include 
observational studies assessing the relationship between the feed and health outcomes, or a 
controlled longer-term follow up study.  This sentinel surveillance is perhaps the most useful 
possible application of routinely collected animal health data for post market monitoring of GM feed 
adverse effects. A simulation tool has been developed in the frame of the MARLON project to help 
design such surveillance systems. The approach consist in estimating, through probabilistic 
modelling, the likelihood of picking up a postulated effect based on frequency of occurrence,  
likelihood of clinical symptoms and likelihood of reporting by farmers, veterinarians and 
laboratories.  
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6. Conclusions 
Several reasons make the design and implementation of animal health surveillance 
challenging in the context of GM, most notably the lack of evidence for known adverse 
effects and lack of a specific test to confirm these effects are related to GM feed. The 
current terminology used in GM feed post market monitoring is also not consistent with 
terminology frequently used in animal health surveillance.  
 
There currently exists large scale monitoring systems in place that gather data and evaluate 
health and production outcomes. It is likely that if there were a major deviation in livestock 
health and production as a result of GM or any other exposure  it would be picked up by the 
existing systems.  
 
Evidence for adverse effects is a pre-requisite for case-specific post-market monitoring and literature 
describing such adverse effects needs to be repeatable. Investment in robustly designed pre-market 
health studies, if the latter are deemed necessary, may provide the strength of evidence required to 
inform decisions in this area of post-market monitoring. Given the lack of published evidence for 
adverse effects on livestock related to GM-feed consumption, it is currently not possible to target a 
surveillance system specifically at such effects.  
 
For adverse effects of unknown cause observed through general surveillance of commonly measured 
generic health parameters, there are difficulties with both a test to associate the adverse effect to a 
particular factor, such as a specific GM product consumed by the animal, and also to quantify the 
exposure of the animal or farm to that particular GM product (50). Surveillance may be a useful alert 
of potential issues that may or may not be related to GM feed. Follow-up to confirm the true cause 
of such changes, such as through controlled studies in livestock animals, would therefore be needed 
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in order to confirm such attribution. The possibility of failing to detect an adverse condition which 
was present and detecting adverse conditions which are not truly present should be considered for 
any post market monitoring system for GM feed. This could be done, for example, with the use of 
probabilistic Monte-Carlo simulation using the approach adopted within the MARLON project. By 
exploring whether ongoing animal health and production surveillance could be expected to detect a 
postulated effect on livestock health, such an approach will support prospective applicants for GM 
products with the design of post-market monitoring programs that will yield meaningful outcomes, if 
required to do so as part of regulatory decisions for market approval under EU legislation. As 
explained in the introduction, post-market monitoring of a specific GM feed can be optionally 
required by decision makers for specific health impacts identified during the pre-market assessment. 
The cost-effectiveness of any surveillance approach to monitor for adverse effect of GM feed is likely 
to be low with a high cost per animal detected. Further work in this area may therefore be 
appropriate to compare its cost-efficiency with that of more controlled studies so as to ensure that 
the approach chosen will be proportionate to a potential health impact involved.   
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Type of Surveillance Activity
Allergenicity
Horizontal Gene Transfer 
/ AMR
Unknown Adverse 
Effects
Beneficial Effects.  Eg Inc 
growth rate. 
Strengths Cheap, infrastructure in place. Low start up costs. 
Higher reporting rate 
than other conditions
Low set up cost. 
Weaknesses
Not specific to allergenicity. 
Prone to type II errors. 
Varies rapidly, not 
specific to GM feed.  
Poor proof of attribution. 
Missclassification may 
be problematic.  Poor 
proof of attribution.
Standard passive system 
would have a low 
specificity here. 
Strengths
Add onto exisiting activities, It 
may be poissible to perform 
DNA analysis on stomach 
contents. 
Swabs and DNA analysis 
could be performed. 
Slaughter line already 
established to evaluate 
for unknown and 
general meat hygine 
issues. 
Evidence of beneficial 
effects eg. carcase weight 
etc. could be evaluated. 
Weaknesses
No evidence gross PM will 
detect and lessions. DNA tests 
would be costly. 
Difficult to show 
attribution, routine 
swabbing and DNA 
testing would be 
extremely costly. 
High probability of false 
negatives. 
Missclassification of the 
cause of the effect. 
Strengths Increased specificity. Increased specificity
Increased compliance & 
specificity. 
Increased specificity. 
Weaknesses
Condition has low detection 
rates. 
Difficult to target on as 
AMR requires in depth 
DNA analysis of feed and 
bacteria to show 
attribution. 
under reporting and 
false positives may occur
May lead to type II error. 
Strengths
Strategic, high exposure farms 
could be used to reduce costs. 
Strategic, high exposure 
farms could be used to 
reduce costs. 
Strategic, high exposure 
farms could be used to 
reduce costs. 
Strategic, high exposure 
farms could be used to 
reduce costs. 
Weaknesses Poorly specific to allergenicity. 
Difficult to show 
attribution, routine 
swabbing and DNA 
testing would be 
under reporting and 
false positives may occur
May lead to type II error. 
Sentinel Surveillance 
Active Targetted
Meat Inspection
Passive / Enhanced Passive
Syndrome of Outcome of Interest  
Table 1: Strengths and Weaknesses of Surveillance programs for GM feed syndromes.  
 
 
